It has been elucidated that lncRNA MEG3 is downregulated in prostate cancer [18], gastric cancer (GC) [19], pancreatic cancer [20], gallbladder cancer (GBC) [21], breast cancer [22], cervical cancer (CECA) [23], hepatocellular carcinoma (HCC) [24] and NSCLC [25], represses cell proliferation and invasion [18–25], and its low expression is associated with distant metastasis and poor prognosis [20–23, 25]. Here, MEG3 is linked to hepatocellular carcinoma.